Artwork

Indhold leveret af Talking About Tumors. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Talking About Tumors eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

04_04 Castrate Resistant Metastatic Prostate Cancer

24:50
 
Del
 

Manage episode 402595979 series 3335024
Indhold leveret af Talking About Tumors. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Talking About Tumors eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

1. On continuation of ADT and ARAT switch
2. Systemic therapy options after progression
3. Improper mandated crossover
4. PARP inhibitors in prostate cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1. Freedland SJ et al. NEJM. 2023;389(16):1453-1465. doi:10.1056/NEJMOA2303974/

2. de Bono J et al. NEJM. 2020;382(22):2091-2102. doi:10.1056/NEJMOA1911440/

3. Haslam A, Prasad V. Annals of Oncology. 2018;29(5):1079. doi:10.1093/ANNONC/MDY116

4. Parker C et al. NEJM. 2013;369(3):213-223. doi:10.1056/NEJMOA1213755/

5. Khalaf DJ et al. Lancet Oncol. 2019;20(12):1730-1739. doi:10.1016/S1470-2045(19)30688-6

6. Saad F et al.. J Natl Cancer Inst. 2004;96(11):879-882. doi:10.1093/JNCI/DJH141

7. Sartor O et al. NEJM. 2021;385(12):1091-1103. doi:10.1056/NEJMOA2107322/

8. de Wit R et al. NEJM. 2019;381(26):2506-2518. doi:10.1056/NEJMOA1911206/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

44 episoder

Artwork
iconDel
 
Manage episode 402595979 series 3335024
Indhold leveret af Talking About Tumors. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Talking About Tumors eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

1. On continuation of ADT and ARAT switch
2. Systemic therapy options after progression
3. Improper mandated crossover
4. PARP inhibitors in prostate cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1. Freedland SJ et al. NEJM. 2023;389(16):1453-1465. doi:10.1056/NEJMOA2303974/

2. de Bono J et al. NEJM. 2020;382(22):2091-2102. doi:10.1056/NEJMOA1911440/

3. Haslam A, Prasad V. Annals of Oncology. 2018;29(5):1079. doi:10.1093/ANNONC/MDY116

4. Parker C et al. NEJM. 2013;369(3):213-223. doi:10.1056/NEJMOA1213755/

5. Khalaf DJ et al. Lancet Oncol. 2019;20(12):1730-1739. doi:10.1016/S1470-2045(19)30688-6

6. Saad F et al.. J Natl Cancer Inst. 2004;96(11):879-882. doi:10.1093/JNCI/DJH141

7. Sartor O et al. NEJM. 2021;385(12):1091-1103. doi:10.1056/NEJMOA2107322/

8. de Wit R et al. NEJM. 2019;381(26):2506-2518. doi:10.1056/NEJMOA1911206/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

44 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning